Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD)   MAY 2014 , Volume 8 , Number 3; Page(s) 231 To 235.
 
Paper: 

PREVALENCE AND RISK FACTORS OF RECURRENT CYTOMEGALOVIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENTS

 
 
Author(s):  NAFAR MOHSEN, ROSHAN AZAMOLSADAT*, POUR REZA GHOLI FATEMEH, SAMADIAN FARIBA, AHMADPOOR PEDRAM, SAMAVAT SHIVA, ABBASI MOHAMMAD AMIN
 
* DEPARTMENT OF INTERNAL MEDICINE, TALEGHANI HOSPITAL, SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN
 
Abstract: 

Introduction. Recurrence of cytomegalovirus (CMV) infection following solid organ transplantation causes mortality and morbidity in allograft recipients. The aim of this study was to evaluate prevalence and risk factors of recurrent CMV infection in kidney transplant patients.
Materials and Methods. Four hundred and twenty-seven consecutive kidney transplant recipients were included in this retrospective cohort study. Both donors and recipients were CMV seropositive. Recurrent CMV infection (symptomatic or asymptomatic) was defined as detection of CMV infection in a patient who has had previously documented infection and who had not have virus detected for an interval of at least 4 weeks during active surveillance.
Results. Of 427 recipients, 71 (16.6%) had CMV infection, of which 19 (4.4%) were recurrent infection. Donor source, dialysis duration before transplantation, recipient and donor age and sex, and administration of antithymocyte globulin and prophylactic treatment ganciclovir were not associated with CMV infection or recurrence. The use of tacrolimus in the immunosuppressive regimen as compared to cyclosporine was an independent risk factor for CMV infection but not recurrent infection.
Conclusions. Intensive immunosuppressive regimen, such as using tacrolimus, might be associated with a higher risk for CMV infection, but this study was not able to document the same association for recurrent CMV disease. In patients receiving immunosuppressive regimens that include tacrolimus and antithymocyte globulin, prophylactic treatment for CMV disease with ganciclovir is recommended.

 
Keyword(s): CYTOMEGALOVIRUS INFECTION, KIDNEY TRANSPLANTATION, GANCICLOVIR
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

NAFAR, M., & ROSHAN, A., & POUR REZA GHOLI, F., & SAMADIAN, F., & AHMADPOOR, P., & SAMAVAT, S., & ABBASI, M. (2014). PREVALENCE AND RISK FACTORS OF RECURRENT CYTOMEGALOVIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENTS. IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD), 8(3), 231-235. https://www.sid.ir/en/journal/ViewPaper.aspx?id=408916



Vancouver: Copy

NAFAR MOHSEN, ROSHAN AZAMOLSADAT, POUR REZA GHOLI FATEMEH, SAMADIAN FARIBA, AHMADPOOR PEDRAM, SAMAVAT SHIVA, ABBASI MOHAMMAD AMIN. PREVALENCE AND RISK FACTORS OF RECURRENT CYTOMEGALOVIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENTS. IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD). 2014 [cited 2021November27];8(3):231-235. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=408916



IEEE: Copy

NAFAR, M., ROSHAN, A., POUR REZA GHOLI, F., SAMADIAN, F., AHMADPOOR, P., SAMAVAT, S., ABBASI, M., 2014. PREVALENCE AND RISK FACTORS OF RECURRENT CYTOMEGALOVIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENTS. IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD), [online] 8(3), pp.231-235. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=408916.



 
  pdf-File
Yearly Visit 57
 
 
Latest on Blog
Enter SID Blog